Literature DB >> 21821834

Post-transplantation encapsulating peritoneal sclerosis in a young child.

Ratna Tan1, Michiel Betjes, Karlien Cransberg.   

Abstract

Encapsulating peritoneal sclerosis (EPS) is a very rare condition in children. Nevertheless, EPS should be considered when a child with a history of peritoneal dialysis (PD) presents with signs of bowel obstruction. We describe a child with post-transplantation EPS and discuss risk factors, diagnosis and treatment options. CT scan should be performed promptly to confirm the diagnosis. Treatment consists of cessation of the PD, if applicable, and adequate nutrition, either parenteral or enteral. Further medical therapy remains controversial but may involve steroids and/or interruption of calcineurin inhibitors.

Entities:  

Mesh:

Year:  2011        PMID: 21821834     DOI: 10.1093/ndt/gfr435

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

Review 1.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

2.  Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient.

Authors:  Nicole da Silva; Sofia Rocha; Liliana Rocha; Sameiro Faria; Teresa Costa; Conceição Mota
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

3.  Successful antibiotic treatment of Pseudomonas stutzeri-induced peritonitis without peritoneal dialysis catheter removal in continuous ambulatory peritoneal dialysis.

Authors:  Sung Wook Park; Ji Hyeon Back; Seoung Woo Lee; Joon Ho Song; Chun Ho Shin; Gyung Eun Kim; Moon-Jae Kim
Journal:  Kidney Res Clin Pract       Date:  2013-05-22

4.  Post-transplantation encapsulating peritoneal sclerosis without inflammation or radiological abnormalities.

Authors:  Sayed Meelad Habib; Frank Johan Marinus Frederik Dor; Mario Richard Korte; Sander Martijn Hagen; Michiel Gerardus Henricus Betjes
Journal:  BMC Nephrol       Date:  2013-09-26       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.